Petal Surgical

Executive Summary

Petal Surgical is pioneering incisionless surgery through its proprietary Acoustic Sculpting technology, a form of boiling histripsy that uses focused sound waves to precisely destroy pathological tissue without incisions, heat, or toxicity. This approach offers a gentler alternative to traditional surgery with potential for faster recovery and reduced complications, initially targeting ophthalmology indications such as glaucoma or cataracts. Founded in 2019 and based in San Francisco, the company is in a pre-commercial stage, having raised seed funding and likely conducting preclinical studies. Its technology could disrupt the surgical market by enabling procedures currently requiring lasers or scalpels to be performed non-invasively, addressing significant unmet needs in patient safety and procedural efficiency.

Upcoming Catalysts (preview)

• Q1 2027First-in-human clinical trial initiation60% success
• Q3 2026FDA Breakthrough Device designation75% success
• Q4 2026Series A funding round80% success